# BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

> **NCT01894672** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** LGX818

## Key facts

- **NCT ID:** NCT01894672
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2016-03-17
- **Final completion:** 2016-03-17
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2024-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01894672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01894672, "BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01894672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*